Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Cinira Lefèvre"'
Autor:
Shuk-Li Collings, Cinira Lefèvre, Michelle E Johnson, David Evans, Guido Hack, Gillian Stynes, Andrew Maguire
Publikováno v:
PLoS ONE, Vol 12, Iss 10, p e0185642 (2017)
This study examined characteristics and treatment persistence among patients prescribed oral anticoagulants (OACs) for stroke prevention in non-valvular atrial fibrillation (NVAF). We identified 15,244 patients (51.8% male, 72.7% aged ≥70) with NVA
Externí odkaz:
https://doaj.org/article/03838fbdf26b496e8434fc93434012fa
Autor:
Hannah Lennon, Guillaume Lefèvre, Mouna Hennaoui, Cinira Lefèvre, Nizar Mahlaoui, Arnaud Nucit, Chahrazed Maherzi, Aurélie Schmidt, Isabelle Borget
Publikováno v:
Revue d'Épidémiologie et de Santé Publique. 69:S96
Contexte et objectifs Les patients atteints de deficits immunitaires primitifs (DIP) ou secondaires (DIS) peuvent recevoir un traitement substitutif de longue duree avec des immunoglobulines sous-cutanees (IgSC). Celles administrees a domicile peuven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6c921bd99470c9b79e75cc36b903efb
https://doi.org/10.1016/j.respe.2021.05.022
https://doi.org/10.1016/j.respe.2021.05.022
Autor:
Raza Alikhan, Cinira Lefevre, Ian Menown, Steven Lister, Alex Bird, Min You, David Evans, Cormac Sammon
Publikováno v:
TH Open, Vol 03, Iss 04, Pp e316-e324 (2019)
Background There is little evidence on how the occurrence of a bleed in individuals on vitamin K antagonists (VKAs) impacts the risk of subsequent bleeds, and thromboembolic and ischemic events. Such information would help to inform treatment decisio
Externí odkaz:
https://doaj.org/article/cf4c084cccc94833a394f49753c0a23b
Autor:
Morten Lamberts, Laila Staerk, Jonas Bjerring Olesen, Emil Loldrup Fosbøl, Morten Lock Hansen, Louise Harboe, Cinira Lefevre, David Evans, Gunnar Hilmar Gislason
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 2 (2017)
BackgroundThe nonvitamin K antagonist oral anticoagulants have recently become available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on real‐life patient experience, including bleeding risk, are lacking. Our
Externí odkaz:
https://doaj.org/article/2aff5885b5dc4cb0b044cadd5c74ed92
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.